Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Aim: The aim of the study was to explore fi ve years survival in women with endometrial cancer. Material and methods: A retrospective review of 146 patients with endometrial cancer treated at Baskent University Hospital Gyne-oncologic Clinic in Ankara, Turkey between 2010 and 2015 was performed. Demographic and clinic-pathological data were compared with survival. Results: The median age of the patients was 61.4 y±5.3 years (36-82). The overall 5-years survival was 89%. Multivariate Cox regression model revealed that the FIGO stage, grade, age, histological type, myometrial invasion, and lymph node involvement were all predictive factors on survival (p<0.05). However, the menopausal status, age at menopause, parity, BMI, comorbidities, ECOG performance score, therapy modality, HR status, and family history were not associated with survival (p>0.05). Conclusion: The results of our study, several clinic-pathological prognostic factors of EC have been identifi ed on survival. These results provided signifi cant evidence that early foresight of EC survival. Further prospective randomized studies are necessary to clarify the role of these factors.
Aim: The aim of the study was to explore fi ve years survival in women with endometrial cancer. Material and methods: A retrospective review of 146 patients with endometrial cancer treated at Baskent University Hospital Gyne-oncologic Clinic in Ankara, Turkey between 2010 and 2015 was performed. Demographic and clinic-pathological data were compared with survival. Results: The median age of the patients was 61.4 y±5.3 years (36-82). The overall 5-years survival was 89%. Multivariate Cox regression model revealed that the FIGO stage, grade, age, histological type, myometrial invasion, and lymph node involvement were all predictive factors on survival (p<0.05). However, the menopausal status, age at menopause, parity, BMI, comorbidities, ECOG performance score, therapy modality, HR status, and family history were not associated with survival (p>0.05). Conclusion: The results of our study, several clinic-pathological prognostic factors of EC have been identifi ed on survival. These results provided signifi cant evidence that early foresight of EC survival. Further prospective randomized studies are necessary to clarify the role of these factors.
BACKGROUND Endometrial carcinoma is a leading malignancy among females. Pre-operative imaging and biopsy are necessary to identify the disease. Clinicopathological analysis determines the extent of the disease. Complete surgical staging is advised for high-risk patients. The purpose of this study was to analyze the different clinical endpoints, prognostic factors and demographic details that will influence the survival patterns of the cases of carcinoma of endometrium who underwent surgery during the period from 2014 to 2017 at a tertiary care centre, Chennai, India. METHODS Patients diagnosed with operable endometrial carcinoma were surgically staged based on the surgical procedures performed namely, total abdominal hysterectomy (TAH) with bilateral salphingo-oophorectomy (BSO), bilateral pelvic lymph node dissection, and para-aortic lymphadenectomy (patients with high-risk features). Post-surgical staging specimens were histopathologically examined in the Department of Pathology. Adjuvant radiation was given to patients with stage IA grade II and above. Patients with stage III disease received adjuvant chemotherapy. Descriptive analysis was done to show the distributions of patients accordingly. Kaplan-Meier survival analysis was performed for the overall median survival of the patients. RESULTS The study consisted of a total of 35 patients with a mean age of 56 ± 8.64. Parameters such as age, clinicopathological features, stage (FIGO staging), tumor size, grade, lymphovascular invasion (LVI), myometrial invasion, cervical involvement, involvement of margins, lymph node ratio (LNR) and survival were studied. Tumor size and grade were found to be significant factors affecting the survival. Overall median survival period of patients who underwent surgery was found to be 31 months. CONCLUSIONS Tumor size and grade of the tumor are significant prognostic factors affecting the survival of the patients with carcinoma of endometrium. Lymph node ratio is a new concept in carcinoma endometrium to be pondered upon as a factor predicting survival in future studies thereby defining the role of lymph node dissection in surgical staging. KEYWORDS Endometrial Cancer, FIGO Staging, Lymph Node Ratio, Prognosis, Survival Analysis
Aims: This study aims to assess the clinicopathological features, treatment, recurrence pattern, survival, and prognostic factors in patients with endometrial carcinoma (EC). Materials and Methods: This was a retrospective study of 64 patients with EC who were diagnosed and treated at our institute from January 2010 to December 2013 and were followed till December end 2019. Survival analysis was done using Kaplan–Meier estimates and significance between curves by using the log-rank test. Results: The mean age of diagnosis was 60 years. The most common complaint was vaginal bleeding (75%). More than half of the patients (52.6%) had high body mass index (BMI). The majority of patients underwent surgery (90.7%) and had the early-stage disease (Stage I in 82.9%). During a median follow-up of 79 months (range: 4–100 months), 18.8% of patients experienced recurrence and vaginal vault (33.3%) was the most common site for recurrence. The 5-year disease-free survival was 83% and the 5-year overall survival was 84.7%. Elderly age, high BMI, advanced disease stage, more than 50% of myometrial invasion, nonendometrioid histology, Grade II and Grade III tumors, lymphovascular space invasion, and lymph node involvement adversely affected long-term survival. Conclusion: EC is mainly a disease of postmenopausal women, and most of them are diagnosed at an early stage and have good survival outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.